|Bid||17.85 x 800|
|Ask||19.80 x 1100|
|Day's Range||18.05 - 19.02|
|52 Week Range||13.70 - 29.90|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.33|
While small-cap stocks, such as Collegium Pharmaceutical, Inc. (NASDAQ:COLL) with its market cap of US$634m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
STOUGHTON, Mass., Nov. 12, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company focused on becoming the leader in responsible pain.
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -127.27% and -6.94%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Canton, Massachusetts-based company said it had a loss of 50 cents per share. Losses, adjusted for non-recurring costs and stock option expense, came to 25 cents per share. The results did not meet ...
Net Product Revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017Thirteen exclusive ER oxycodone formulary wins announced for.
Don't be caught off-guard: Collegium Pharmaceutical, Inc. - Common Stock (NASDAQ: COLL ) releases its next round of earnings this Thursday, Nov. 8. View more earnings on COLL Want to skip the homework ...
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STOUGHTON, Mass., Oct. 29, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the publication of “Evaluation of the oral human abuse potential of Oxycodone.
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
STOUGHTON, Mass., Oct. 17, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.
STOUGHTON, Mass., Sept. 28, 2018-- Collegium Pharmaceutical, Inc. today announced that management will present at the following investor conference in October:. The Cantor Global Healthcare Conference ...
Collegium Pharmaceutical’s net loss decreased from $21.12 million in the second quarter of 2017 to $13.06 million in the second quarter of 2018, which translated into a net loss per share of $0.40 in the second quarter as compared with a net loss per share of $0.72 in the second quarter of 2017. In August 2018, of the total eight analysts covering Collegium Pharmaceutical, three analysts have given the stock a “strong buy” rating, and five analysts have given Collegium Pharmaceutical a “buy” rating. The mean rating for Collegium Pharmaceutical stock is 1.63 with a target price of $31.67.
Collegium Pharmaceutical (COLL) is a specialty pharmaceutical company focused on bringing to market products for people suffering from pain. In January 2018, Collegium began commercializing Nucynta products. Collegium Pharmaceutical generated total revenues of $73.06 million in the second quarter of 2018 as compared with $3.56 million in the second quarter of 2017.
The US government is taking steps to address the opioid epidemic and rapidly rising addiction levels in the country. On August 16, President Trump asked the Attorney General to start filing federal lawsuits against certain companies that supply opioids to hospitals. In this series, we’ll analyze the financial performance, products, analysts’ views, valuation metrics, and the stock performance of Insys Therapeutics (INSY), Cara Therapeutics (CARA), Collegium Pharmaceutical (COLL), and Pacira Pharmaceuticals (PCRX).
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 65.91% and 4.06%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Collegium Pharmaceutical, Inc. (NASDAQ: COLL ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern ...
On Wednesday, Collegium Pharmaceutical (NASDAQ: COLL ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Analysts ...
WallStEquities.com revisits the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the generic drugs market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. Under assessment this morning are these four stocks: Agile Therapeutics Inc. (NASDAQ: AGRX), Akorn Inc. (NASDAQ: AKRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), and Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX).